Therefore, the aim of the present study was to investigate whether insulin glargine was able to reduce the risk of cardiovascular events and improve β-cell function and insulin sensitivity in T2D patients with a high risk for cardiovascular disease. This evidence concerns the gene INS and type 2 diabetes mellitus.